To The Moon

Could Iovance (IOVA) be the next 100x biotech stock? Its FDA-approved TIL therapy Amtagvi is making waves in melanoma, with NSCLC trials on the horizon! But will the complex production process and regulatory risks derail its potential?

Are you willing to bet on this "miracle cancer drug" or steering clear of the high uncertainty? Share your thoughts on IOVA below!

In the biotech sector, some stocks are labeled "penny stocks" due to extreme uncertainty—but it’s precisely this uncertainty that can harbor astonishing growth potential. $Iovance Biotherapeutics, Inc.(IOVA)$ is one such company: its flagship product Amtagvi, a customized cancer drug derived from patients’ own immune cells, features a complex and time-consuming production process yet has demonstrated unique efficacy in treating melanoma.

Since receiving U.S. FDA approval in early 2024, Amtagvi’s commercialization has progressed steadily, but the stock price has remained lackluster. However, if the drug successfully expands into new markets and secures additional indications in the coming years, Iovance could evolve into the next 10x or even 100x stock.

A "Living Drug" Born from Patient Cells

Amtagvi is a tumor-infiltrating lymphocyte (TIL) therapy that extracts patients’ own cancer-fighting immune cells, expands them in vitro, and reinfuses them back into the patient’s body. This highly personalized treatment offers a novel option for patients with advanced melanoma. Following its 2024 approval, Iovance quickly launched the drug commercially. In fiscal 2025, the company generated total revenue of $263.5 million, a 60.6% year-on-year increase, with the vast majority coming from Amtagvi sales.

While the stock price hasn’t surged since the drug’s launch, sales growth momentum remains strong. More importantly, Iovance is actively expanding into global markets: the drug has been approved in Canada, with regulatory reviews underway in the European Union, the United Kingdom, and Australia. The opening of these new markets will bring fresh growth opportunities for Amtagvi.

Next Blockbuster Indication: Non-Small Cell Lung Cancer

Beyond melanoma, Amtagvi has the potential to enter the larger cancer treatment space. The company has initiated multiple clinical trials to explore its efficacy in solid tumors such as non-small cell lung cancer (NSCLC). The U.S. FDA has granted Fast Track designation for NSCLC, signaling the drug’s potential to address unmet medical needs. Additionally, a small early-stage clinical study targeting certain rare cancers has yielded positive results.

If Amtagvi can gain a foothold in the massive NSCLC market, Iovance’s revenue is expected to reach new heights, driving a corresponding surge in its stock price. Analysts generally agree that the next decade will be a critical window to validate its potential.

The High-Risk Path of "Customization"

However, Amtagvi’s complexity poses significant challenges for Iovance. The entire process—from collecting patient cells and transporting them to production facilities, to 34 days of personalized manufacturing, and finally to intravenous reinfusion after the patient receives chemotherapy—requires highly coordinated specialized centers and technical teams. This not only limits treatment accessibility but also drastically increases costs, making it difficult for the company to achieve profitability in the short term.

Furthermore, as a small biotech firm, Iovance must contend with inherent risks in clinical development and regulatory approval. Any trial failure or approval delay could severely impact the stock price. Thus, while Amtagvi’s prospects are promising, the underlying uncertainty cannot be overlooked.

Investment Insight: Balancing Risk and Ambition

For investors willing to take on high risk, Iovance represents a classic "all-or-nothing, 100x potential" opportunity. If Amtagvi successfully penetrates major global markets, secures blockbuster indications like NSCLC, and the company optimizes production processes to reduce costs over the next decade, Iovance’s stock price indeed holds enormous upside potential. Conversely, setbacks in clinical trials or commercialization could lead to significant losses for investors.

Like all penny stock investments, the key lies in conducting thorough research, diversifying risk, and clearly understanding one’s risk tolerance. Iovance’s story is far from over—it stands at the crossroads of opportunity and challenge, waiting for time to deliver the verdict.

For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.

🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now

Find out more here.

Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.

Click to access the activity

Other helpful links:

• 💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉

• How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.